Cambridge, United Kingdom-based biopharmaceutical company transforming the lives of patients through a novel class of in vivo reprogramming therapies, Mogrify raised an additional USD 10 million in funding. The company announced the investment on October 2, 2023. Strategic corporate investors Astellas Venture Management and Parkwalk Advisors co-led the financing for the company. In addition, the leading funder of UK university spin-outs along with Ahren Innovation Capital, Trend Investment Group, and Dr Jonathan Milner, co-founder of Abcam Plc. provided the investment to Mogrify.
Purpose of financing for Mogrify
With the latest financing, Mogrify seeks to support further advancement of its pipeline of in vivo reprogramming therapies through pre-clinical translation, continued platform optimization, and facilitation of new and existing biopharma collaborations.
What the company’s official has to add
Dr. Darrin M. Disley OBE, CEO, Mogrify, said, “We are delighted to receive the continued support of Astellas Venture Management, Parkwalk Advisors and other existing investors as we relentlessly focus on progressing our novel pipeline of in vivo reprogramming therapies through pre-clinical-translation-.. Aligned to a consolidated corporate structure and vision, this latest funding will provide sufficient cash runway to enable the achievement of key development milestones in both our internal programs as well as those being developed in collaboration with strategic partners. Existing investor commitment is a testament to our delivery of world-class science, expertise in cellular reprogramming and the unique potential of the MOGRIFY platform to deliver novel regenerative medicines to improve the lives of a broad spectrum of patients.”
What the investors have to comment
Tadayoshi Hirata, Senior Investment Manager, Astellas Venture Management, further said, “Mogrify has made significant progress in the development and commercialization of its technology and is uniquely positioned to address a rapidly growing regenerative medicine market. In addition to the collaboration between our parent company Astellas Pharma Inc. and Mogrify in the context of sensorineural hearing loss that began in July 2022, we are pleased to continue to support the company and its exploitation of the MOGRIFY platform as an investor.”
Besides, Alastair Kilgour, Chief Investment Officer, Parkwalk Advisors, commented, “The Mogrify team continues to progress a robust scientific and commercial strategy, aligned to the USP of the technology in generating novel in vivo reprogramming therapies that have the potential to deliver transformative outcomes for patients. We are excited to continue supporting the leadership and scientific teams as they realize the next set of translational milestones.”
About the company
In 2019, Jose Polo, Julian Gough, and Owen Rackham launched the company. Mogrify’s proprietary platform technologies enable systematic identification of the key transcriptomic and epigenetic cell switches required to control human cell fate.
For more extensive analysis and Market Intelligence reports, feel free to approach us.
We try our best to fact-check and bring well-researched as well as non-plagiarized content to you. Please let us know
if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover
–what information you are looking for in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!
Next Article
